Autopsy report · NCT01712399

A Long Term Safety Study of Mavrilimumab in Adult Subjects With Rheumatoid Arthritis

“The study was terminated after approximately 3 years due to future clinical development plans, including ethical considerations.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 3 months before it started.
• Ran for about 2 years 11 months before it stopped.
• 409 participants enrolled.
• Results were posted on the registry 1 year 5 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

MedImmune LLC

Sponsor type

Industry

Conditions

Rheumatoid Arthritis

Interventions

Mavrilimumab 100 mg

Participants

409

Sites

52

Countries

Argentina, Bulgaria, Chile, Colombia, Czechia, Estonia, Germany, Greece, Hungary, Israel, Mexico, Poland and more

Trials that died the same way

• A Phase 1 Clinical Study of NXP800 in Subjects With Advanced Cancers and Expansion in Subjects With Ovarian Cancer
  “Study terminated due to various reasons impacting the feasibility of future clinical development” (84% match in meaning)
• Surgical Intervention in Bariatric Patients: Excess Weight Loss in the Morbidly Obese Following Gastric Plication
  “Study was terminated due to commercial considerations and potential patient attrition at 3 years. There were no patient safety or procedure efficacy reasons.” (82% match in meaning)
• Study To Determine The Pharmacokinetics Of Sulfasalazine In Children With Juvenile Idiopathic Arthritis
  “Study terminated on 13 April 2016 for business reasons. No safety and/or efficacy concerns contributed to the termination of the study” (79% match in meaning)
• A Study of Tivozanib in Combination With Durvalumab in Subjects With Advanced Hepatocellular Carcinoma
  “The study was terminated due to regulatory approval of newer therapeutic options and slower than anticipated accrual.” (79% match in meaning)
• A Long-Term Safety And Tolerability Study Of Bapineuzumab In Alzheimer Disease Patients
  “The study was terminated on August 6, 2012, because 2 large Phase 3 studies showed no clinical benefit. This decision was not based on any new safety concerns.” (78% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.